

Nananda Col

List of Publications by Citations

Source: <https://exaly.com/author-pdf/1008267/nananda-col-publications-by-citations.pdf>

Version: 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

65
papers

5,050
citations

26
h-index

66
g-index

66
ext. papers

5,689
ext. citations

4.6
avg, IF

5.06
L-index

#	Paper	IF	Citations
65	Subclinical thyroid disease: scientific review and guidelines for diagnosis and management. <i>JAMA - Journal of the American Medical Association</i> , 2004 , 291, 228-38	27.4	1163
64	Estimating hip fracture morbidity, mortality and costs. <i>Journal of the American Geriatrics Society</i> , 2003 , 51, 364-70	5.6	612
63	Assessing the quality of decision support technologies using the International Patient Decision Aid Standards instrument (IPDASi). <i>PLoS ONE</i> , 2009 , 4, e4705	3.7	291
62	Meta-analysis of vascular and neoplastic events associated with tamoxifen. <i>Journal of General Internal Medicine</i> , 2003 , 18, 937-47	4	286
61	Communicating the uncertainty of harms and benefits of medical interventions. <i>Medical Decision Making</i> , 2007 , 27, 681-95	2.5	237
60	Use of pharmacologic interventions for breast cancer risk reduction: American Society of Clinical Oncology clinical practice guideline. <i>Journal of Clinical Oncology</i> , 2013 , 31, 2942-62	2.2	230
59	American society of clinical oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction. <i>Journal of Clinical Oncology</i> , 2009 , 27, 3235-58	2.2	223
58	Do patient decision aids meet effectiveness criteria of the international patient decision aid standards collaboration? A systematic review and meta-analysis. <i>Medical Decision Making</i> , 2007 , 27, 554-74	2.4	196
57	American Society of Clinical Oncology technology assessment of pharmacologic interventions for breast cancer risk reduction including tamoxifen, raloxifene, and aromatase inhibition. <i>Journal of Clinical Oncology</i> , 2002 , 20, 3328-43	2.2	166
56	Clarifying values: an updated review. <i>BMC Medical Informatics and Decision Making</i> , 2013 , 13 Suppl 2, S8	3.6	156
55	Metformin and breast cancer risk: a meta-analysis and critical literature review. <i>Breast Cancer Research and Treatment</i> , 2012 , 135, 639-46	4.4	156
54	Revisiting the duration of vasomotor symptoms of menopause: a meta-analysis. <i>Journal of General Internal Medicine</i> , 2008 , 23, 1507-13	4	150
53	Subclinical thyroid disease: clinical applications. <i>JAMA - Journal of the American Medical Association</i> , 2004 , 291, 239-43	27.4	106
52	Hormone replacement therapy after breast cancer: a systematic review and quantitative assessment of risk. <i>Journal of Clinical Oncology</i> , 2001 , 19, 2357-63	2.2	106
51	Duration of vasomotor symptoms in middle-aged women: a longitudinal study. <i>Menopause</i> , 2009 , 16, 453-7	2.5	97
50	Design Features of Explicit Values Clarification Methods: A Systematic Review. <i>Medical Decision Making</i> , 2016 , 36, 453-71	2.5	72
49	Internet use among community college students: implications in designing healthcare interventions. <i>Journal of American College Health</i> , 2004 , 52, 197-202	2.2	63

48	Gender differences and factors associated with the receipt of thrombolytic therapy in patients with acute myocardial infarction: a community-wide perspective. <i>American Heart Journal</i> , 1996 , 131, 43-50	4.9	59
47	Balancing the presentation of information and options in patient decision aids: an updated review. <i>BMC Medical Informatics and Decision Making</i> , 2013 , 13 Suppl 2, S6	3.6	54
46	Effects of Design Features of Explicit Values Clarification Methods: A Systematic Review. <i>Medical Decision Making</i> , 2016 , 36, 760-76	2.5	37
45	Effect of a patient decision aid (PDA) for type 2 diabetes on knowledge, decisional self-efficacy, and decisional conflict. <i>BMC Health Services Research</i> , 2016 , 16, 10	2.9	36
44	The discrepancy between observational studies and randomized trials of menopausal hormone therapy: did expectations shape experience?. <i>Annals of Internal Medicine</i> , 2003 , 139, 923-9	8	36
43	What Families Need and Physicians Deliver: Contrasting Communication Preferences Between Surrogate Decision-Makers and Physicians During Outcome Prognostication in Critically Ill TBI Patients. <i>Neurocritical Care</i> , 2017 , 27, 154-162	3.3	34
42	Decision Aids and Shared Decision-Making in Neurocritical Care: An Unmet Need in Our NeuroICUs. <i>Neurocritical Care</i> , 2015 , 23, 127-30	3.3	32
41	Factors associated with treatment of women with osteoporosis or osteopenia from a national survey. <i>BMC Womens Health</i> , 2012 , 12, 1	2.9	31
40	A latent class typology of young women smokers. <i>Addiction</i> , 2007 , 102, 1310-9	4.6	31
39	Frequency of inclusion of patients with cardiogenic shock in trials of thrombolytic therapy. <i>American Journal of Cardiology</i> , 1994 , 73, 149-57	3	25
38	Whose Preferences Matter? A Patient-Centered Approach for Eliciting Treatment Goals. <i>Medical Decision Making</i> , 2018 , 38, 44-55	2.5	25
37	Estrogen deficiency symptom management in breast cancer survivors in the changing context of menopausal hormone therapy. <i>Seminars in Oncology</i> , 2003 , 30, 776-88	5.5	24
36	Can computerized decision support help patients make complex treatment decisions? A randomized controlled trial of an individualized menopause decision aid. <i>Medical Decision Making</i> , 2007 , 27, 585-98	2.5	23
35	Coronary heart disease and stroke with aromatase inhibitor, tamoxifen, and menopausal hormone therapy use. <i>Clinical Breast Cancer</i> , 2006 , 6 Suppl 2, S58-64	3	23
34	Interprofessional education about shared decision making for patients in primary care settings. <i>Journal of Interprofessional Care</i> , 2011 , 25, 409-15	2.7	22
33	Menopausal hormone therapy after breast cancer. <i>Lancet, The</i> , 2004 , 363, 410-1	4.0	20
32	Women Like Me. <i>Journal of Psychosocial Oncology</i> , 2002 , 20, 39-56	2.8	20
31	Benefit/risk for adjuvant breast cancer therapy with tamoxifen or aromatase inhibitor use by age, and race/ethnicity. <i>Breast Cancer Research and Treatment</i> , 2015 , 154, 609-16	4.4	16

30	Development of a patient decision aid for type 2 diabetes mellitus for patients not achieving glycemic control on metformin alone. <i>Patient Preference and Adherence</i> , 2015 , 9, 609-17	2.4	16
29	Bisphosphonates and breast cancer prevention. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2012 , 12, 144-50	5.0	15
28	Bisphosphonates and breast cancer incidence and recurrence. <i>Breast Disease</i> , 2011 , 33, 93-101	1.6	14
27	Hormone therapy for the prevention of bone loss in menopausal women with osteopenia: is it a viable option?. <i>Drugs</i> , 2007 , 67, 2311-21	12.1	14
26	Ovarian suppression in combination endocrine adjuvant therapy in premenopausal women with early breast cancer. <i>Breast Cancer Research and Treatment</i> , 2017 , 161, 185-190	4.4	13
25	Development of a shared decision-making tool to assist patients and clinicians with decisions on oral anticoagulant treatment for atrial fibrillation. <i>Current Medical Research and Opinion</i> , 2015 , 31, 2261-72	7.5	12
24	The use of gene tests to detect hereditary predisposition to chronic disease: is cost-effectiveness analysis relevant?. <i>Medical Decision Making</i> , 2003 , 23, 441-8	2.5	11
23	The health care information directive. <i>BMC Medical Informatics and Decision Making</i> , 2001 , 1, 1	3.6	10
22	Measuring the impact of menopausal symptoms on quality of life: methodological considerations. <i>Menopause</i> , 2009 , 16, 843-5	2.5	8
21	Commentary--surgical decisions after breast cancer: can patients be too involved in decision making?. <i>Health Services Research</i> , 2005 , 40, 769-79	3.4	8
20	Survival impact of tamoxifen use for breast cancer risk reduction: projections from a patient-specific Markov model. <i>Medical Decision Making</i> , 2002 , 22, 386-93	2.5	8
19	Perceived Effectiveness, Self-efficacy, and Social Support for Oral Appliance Therapy Among Older Veterans With Obstructive Sleep Apnea. <i>Clinical Therapeutics</i> , 2016 , 38, 2407-2415	3.5	8
18	Should We Use the IMPACT-Model for the Outcome Prognostication of TBI Patients? A Qualitative Study Assessing Physicians' Perceptions. <i>MDM Policy and Practice</i> , 2018 , 3, 2381468318757987	1.5	7
17	Impact and Feasibility of Personalized Decision Support for Older Patients with Diabetes: A Pilot Randomized Trial. <i>Medical Decision Making</i> , 2017 , 37, 611-617	2.5	6
16	Using Internet technologies to improve and simplify counseling about menopause: the WISDOM website. <i>Maturitas</i> , 2007 , 57, 95-9	5	6
15	Should menopausal women at increased risk for breast cancer use tamoxifen, raloxifene, or hormone therapy?: a framework for personalized risk assessment and counseling. <i>Journal of Cancer Education</i> , 2007 , 22, 10-4	1.8	5
14	Evaluation of a Novel Preference Assessment Tool for Patients with Multiple Sclerosis. <i>International Journal of MS Care</i> , 2018 , 20, 260-267	2.3	5
13	Improving patient-provider communication about chronic pain: development and feasibility testing of a shared decision-making tool. <i>BMC Medical Informatics and Decision Making</i> , 2020 , 20, 267	3.6	4

12	Efficacy of a patient decision aid for improving person-centered decision-making by older adults with obstructive sleep apnea. <i>Journal of Clinical Sleep Medicine</i> , 2021 , 17, 121-128	3.1	4
11	Patient-Provider Communication With Older Adults About Sleep Apnea Diagnosis and Treatment. <i>Behavioral Sleep Medicine</i> , 2017 , 15, 423-437	4.2	3
10	Patient-Reported Usability of Positive Airway Pressure Equipment Is Associated With Adherence in Older Adults. <i>Sleep</i> , 2017 , 40,	1.1	3
9	Changing Patients' Treatment Preferences and Values with a Decision Aid for Type 2 Diabetes Mellitus: Results from the Treatment Arm of a Randomized Controlled Trial. <i>Diabetes Therapy</i> , 2018 , 9, 803-814	3.6	3
8	Risks and benefits of therapy with menopausal hormones versus selective estrogen-receptor modulators in peri- and postmenopausal women at increased breast cancer risk. <i>Menopause</i> , 2008 , 15, 804-9	2.5	3
7	Consumers and Clinical Decision Support 2014 , 741-769		2
6	Development of a Program Promoting Person-Centered Care of Older Adults with Sleep Apnea. <i>Journal of the American Geriatrics Society</i> , 2019 , 67, 2204-2207	5.6	1
5	A Novel Tool to Improve Shared Decision Making and Adherence in Multiple Sclerosis: Development and Preliminary Testing. <i>MDM Policy and Practice</i> , 2019 , 4, 2381468319879134	1.5	1
4	Re: Pharmacogenomic variation of CYP2D6 and the choice of optimal adjuvant endocrine therapy for postmenopausal breast cancer: a modeling analysis. <i>Journal of the National Cancer Institute</i> , 2008 , 100, 1331-2; author reply 132-3	9.7	1
3	The pitfalls of non-evidence-based guidelines. <i>Menopause</i> , 2006 , 13, 334-7	2.5	1
2	Postmenopausal women with DCIS post-mastectomy: a potential role for aromatase inhibitors. <i>Breast Journal</i> , 2012 , 18, 299-302	1.2	0
1	Hormone replacement therapy after diagnosis of breast cancer did not increase breast cancer recurrence. <i>Evidence-Based Obstetrics and Gynecology</i> , 2002 , 4, 94-95		